Skip to main content
. 2017 Dec 17;9(4):4522–4536. doi: 10.18632/oncotarget.23393

Figure 3.

Figure 3

Receiver operating characteristic curve of (A) phosphatidylglicerol 33:0 (PG (33:0), (B) phosphatidic acid 41:2 (PA (41:2)), (C) diacylglycerol 44:6 (DG (44:6)) and (D) PA (39:3).